134 related articles for article (PubMed ID: 6314716)
1. [Comparative study of the reactogenicity and immunogenicity of new Soviet and commercial vaccines for preventing Japanese encephalitis].
Sumarovkov AA; Grachev VP; Kharazian EG; Shkol'nik RIa; Vorob'eva MS
Zh Mikrobiol Epidemiol Immunobiol; 1983 Sep; (9):74-9. PubMed ID: 6314716
[TBL] [Abstract][Full Text] [Related]
2. [Determination of the optimal dose of a cultured inactivated vaccine for preventing Japanese encephalitis].
Grachev VP; Sumarokov AA; Kharazian EG; Shkol'nik RIa; Karinskaia GA
Zh Mikrobiol Epidemiol Immunobiol; 1984 Jan; (1):98-103. PubMed ID: 6322486
[TBL] [Abstract][Full Text] [Related]
3. Japanese encephalitis vaccines.
Wkly Epidemiol Rec; 1998 Oct; 73(44):337-44. PubMed ID: 9817024
[No Abstract] [Full Text] [Related]
4. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
5. Japanese encephalitis. Inactivated Japanese encephalitis virus vaccine.
Wkly Epidemiol Rec; 1994 Apr; 69(16):113-8. PubMed ID: 8003406
[No Abstract] [Full Text] [Related]
6. [Reactogenicity and antigenic activity of a chromatographic cultured purified and concentrated inactivated dried vaccine against tick-borne encephalitis].
Popov OV; Sumarokov AA; Shkol'nik RIa; El'bert LB; Vorob'eva MS
Zh Mikrobiol Epidemiol Immunobiol; 1985 Jun; (6):34-9. PubMed ID: 3898672
[TBL] [Abstract][Full Text] [Related]
7. Protection against Japanese encephalitis by inactivated vaccines.
Hoke CH; Nisalak A; Sangawhipa N; Jatanasen S; Laorakapongse T; Innis BL; Kotchasenee S; Gingrich JB; Latendresse J; Fukai K
N Engl J Med; 1988 Sep; 319(10):608-14. PubMed ID: 2842677
[TBL] [Abstract][Full Text] [Related]
8. Further experience with Japanese encephalitis vaccine.
Sanchez JL; Hoke CH; McCown J; DeFraites RF; Takafuji ET; Diniega BM; Pang LW
Lancet; 1990 Apr; 335(8695):972-3. PubMed ID: 1970043
[No Abstract] [Full Text] [Related]
9. [Inactivated vaccine against Japanese encephalitis. The characteristics of a purified preparation from mouse brain].
El'bert LB; Semenov BF; Karaseva PS; Pervikov IuV; Krutianskaia GL
Vopr Virusol; 1983; (2):196-200. PubMed ID: 6346687
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
[TBL] [Abstract][Full Text] [Related]
11. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep; 1993 Jan; 42(RR-1):1-15. PubMed ID: 8381504
[TBL] [Abstract][Full Text] [Related]
12. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children.
Xin YY; Ming ZG; Peng GY; Jian A; Min LH
Am J Trop Med Hyg; 1988 Aug; 39(2):214-7. PubMed ID: 2841880
[TBL] [Abstract][Full Text] [Related]
13. Is a booster dose necessary in children after immunization with live attenuated Japanese encephalitis vaccine?
Choi UY; Lee SY; Kim KH; Kim DS; Choi KM; Cha SH; Kang JH
J Trop Pediatr; 2013 Oct; 59(5):423-5. PubMed ID: 23764540
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
Li Y; Chu SY; Yue C; Wannemuehler K; Xie S; Zhang F; Wang Y; Zhang Y; Ma R; Li Y; Zuo Z; Rodewald L; Xiao Q; Feng Z; Wang H; An Z
Lancet Infect Dis; 2019 Apr; 19(4):402-409. PubMed ID: 30833160
[TBL] [Abstract][Full Text] [Related]
15. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines.
Markoff L
Vaccine; 2000 May; 18 Suppl 2():26-32. PubMed ID: 10821970
[TBL] [Abstract][Full Text] [Related]
16. Safety & efficacy of Japanese encephalitis vaccine produced in India.
Rao Bhau LN; Singh G; Gowal D; Saxena SN; Kobayashi M; Oya A; Yoshioka I
Indian J Med Res; 1988 Oct; 88():301-7. PubMed ID: 2852169
[No Abstract] [Full Text] [Related]
17. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
Kanesa-thasan N; Smucny JJ; Hoke CH; Marks DH; Konishi E; Kurane I; Tang DB; Vaughn DW; Mason PW; Shope RE
Vaccine; 2000 Oct; 19(4-5):483-91. PubMed ID: 11027812
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
[TBL] [Abstract][Full Text] [Related]
20. Effect of current Japanese encephalitis vaccine on different strains of Japanese encephalitis virus.
Okuno Y; Okamoto Y; Yamada A; Baba K; Yabuuchi H
Vaccine; 1987 Jun; 5(2):128-32. PubMed ID: 3037813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
